Easy Diagnosis released a performance preview on the evening of January 30, expecting 2022 net profit attributable to shareholders of listed companies of CNY4.6 billion to CNY5 billion, an increase of 225.5% to 253.8%; basic earnings per share of about CNY29.99 to CNY32.60.

The main reason for the change in performance is that in 2022, the outbreak of Omicron epidemic in many places in China has increased the frequency of Covid-19 nucleic acid testing and increased the demand for Covid-19 nucleic acid testing reagents for the prevention and control of the epidemic.

In March 2022, the State Council Joint Prevention and Control Mechanism Integrated Group decided to add antigen testing as a supplement to nucleic acid testing. As one of the first licensed suppliers of neo-crown antigen testing reagents, the company's "Dr. Minghui" neo-crown antigen testing reagents played an important role in the prevention and control of the epidemic in Shanghai in April 2022 and in the auxiliary diagnosis of the surge of infected people in December 2022, which led to significant growth in operating results.